Treats salt and water retention. ANDA 213827, held by Innogenix. Metolazone.
As of Nov 16, 2026, ANDA 213827 (Metolazone), held by Innogenix, was first approved by FDA on Mar 30, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 2021 | Original application | Approved | None posted |
| Metolazone2.5MG · tablet;oral | Metolazone | Rx |
| Metolazone5MG · tablet;oral | Metolazone | Rx |
| Metolazone10MG · tablet;oral | Metolazone | Rx |
| Jan 7, 2026 | Supplement 3Manufacturing | Approved | None posted |
| Mar 30, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters